RANCHO CORDOVA, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Dalip Sethi, Ph.D., senior director of research and development, will present at Cell & Gene Therapy Bioprocessing & Commercialization 2017, which is being held September 25-28 at the Hynes Convention Center in Boston. The conference is part of Biotech Week Boston.
Dr. Sethi’s presentation, entitled “Designing Clinical Trials for Success,” is scheduled for Wednesday, September 27 at 3:00pm ET. His presentation will address, among other topics, the optimal design for late-stage clinical trials, as well as the factors to be considered by drug developers when deciding between conditional or full approval pathways.
For more information, please visit https://lifesciences.knect365.com/cell-therapy-bioprocessing
About the Cell & Gene Therapy Bioprocessing and Commercialization Conference
Cell & Gene Therapy Bioprocessing & Commercialization 2017 is a gathering of leading industry experts focused on relieving bottlenecks and pain points in the clinical development, manufacture and commercialization of cell, gene and immunotherapies.
About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics’ annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc.